DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

VANCOUVER, British Columbia and MENLO PARK, Calif., June 22, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the develop…Read More »

DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference

VANCOUVER, British Columbia and MENLO PARK, Calif., June 16, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “The Company”), a biopharmaceutical company focused on the develop…Read More »

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results

- Company will host a business update conference call and webcast on Wednesday May 24, 2017 at 4:30 PM EST – VANCOUVER, British Columbia and MENLO PARK, Calif., May 18, 2017 /PRNewswire/ — DelMar Pha…Read More »

DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)

VANCOUVER, British Columbia and MENLO PARK, Calif., May 11, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on developing n…Read More »

DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)

VANCOUVER, British Columbia and MENLO PARK, Calif., May 8, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on developing ne…Read More »

Forward Looking Statements

Any statements contained in this blog that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

This Blog is official and sanctioned by DelMar Pharmaceuticals, Inc.

Get DelMar Pharmaceuticals, Inc. Blog Post Alerts